TY - JOUR
T1 - Pharmacokinetics, toxicity, and short-term results of cisplatin hyperthermic isolated limb perfusion for soft-tissue sarcoma and melanoma of the extremities
AU - Pommier, Rodney F.
AU - Moseley, H. Stephens
AU - Cohen, Jordan
AU - Huang, Chu S.
AU - Townsend, Rae Ann
AU - Fletcher, William S.
N1 - Funding Information:
From the Division of Surgical Oncology, Oregon Health Sciences University, Portland, Oregon. Supported in part by the American Cancer Society Clinical Fellowship no. 87191, the OregOn Chapter of the Order of the Eastern Star, and the Ladies Auxiliary of the Veterans of Foreign Wars, Portland, Oregon.
PY - 1988/5
Y1 - 1988/5
N2 - Fifty-nine patients with melanoma or soft tissue sarcoma of the extremities underwent hyperthermic isolated limb perfusion utilizing cisplatin and wide local excision. Doses of cisplatin ranged from 0.75 to 2 mg/kg. The mortality and morbidity rates were 0 and 6.8 percent, respectively. Pharmacokinetic studies indicate that cisplatin is rapidly bound to perfused tissues and remains bound for 1 month. Maximum tumor response in sarcomas occurs 1 to 2 weeks after perfusion, compared with 1 month after perfusions with l-phenylalanine mustard and actinomycin D. Local and regional recurrence rates were 0 and 3.4 percent, respectively, at 1 year. Further studies of hyperthermic limb perfusions with cisplatin are warranted.
AB - Fifty-nine patients with melanoma or soft tissue sarcoma of the extremities underwent hyperthermic isolated limb perfusion utilizing cisplatin and wide local excision. Doses of cisplatin ranged from 0.75 to 2 mg/kg. The mortality and morbidity rates were 0 and 6.8 percent, respectively. Pharmacokinetic studies indicate that cisplatin is rapidly bound to perfused tissues and remains bound for 1 month. Maximum tumor response in sarcomas occurs 1 to 2 weeks after perfusion, compared with 1 month after perfusions with l-phenylalanine mustard and actinomycin D. Local and regional recurrence rates were 0 and 3.4 percent, respectively, at 1 year. Further studies of hyperthermic limb perfusions with cisplatin are warranted.
UR - http://www.scopus.com/inward/record.url?scp=0023932984&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023932984&partnerID=8YFLogxK
U2 - 10.1016/S0002-9610(88)80140-5
DO - 10.1016/S0002-9610(88)80140-5
M3 - Article
C2 - 3369621
AN - SCOPUS:0023932984
SN - 0002-9610
VL - 155
SP - 667
EP - 671
JO - The American Journal of Surgery
JF - The American Journal of Surgery
IS - 5
ER -